Table 1 Characteristics of manuscripts studied and outcome series extracted
| Â | Manuscripts, N = 115 | DLT series, N = 155 | OR series, N = 93 |
|---|---|---|---|
Year of publication | Â | Â | Â |
2008 | 13 (11%) | 17 (11%) | 13 (14%) |
2009 | 9 (7.8%) | 14 (9.0%) | 10 (11%) |
2010 | 9 (7.8%) | 10 (6.5%) | 8 (8.6%) |
2011 | 20 (17%) | 23 (15%) | 11 (12%) |
2012 | 26 (23%) | 35 (23%) | 23 (25%) |
2013 | 16 (14%) | 22 (14%) | 16 (17%) |
2014 | 22 (19%) | 34 (22%) | 12 (13%) |
Experimental design | Â | Â | Â |
Model-based | 85 (74%) | 116 (75%) | 56 (60%) |
Rule-based | 30 (26%) | 39 (25%) | 37 (40%) |
Disease class | Â | Â | Â |
Non-haematological | 82 (71%) | 117 (75%) | 71 (76%) |
Haematological | 30 (26%) | 31 (20%) | 18 (19%) |
Both | 2 (1.7%) | 6 (3.9%) | 4 (4.3%) |
Not disclosed | 1 (0.9%) | 1 (0.6%) | 0 (0%) |
Disease | Â | Â | Â |
Solid tumours | Â | 48 (31%) | 29 (31%) |
Breast cancer | Â | 9 (5.8%) | 8 (8.6%) |
Gastrointestinal cancer | Â | 10 (6.5%) | 6 (6.5%) |
AML | Â | 7 (4.5%) | 6 (6.5%) |
Lung cancer | Â | 9 (5.8%) | 3 (3.2%) |
Lymphoma | Â | 6 (3.9%) | 5 (5.4%) |
Multiple myeloma | Â | 6 (3.9%) | 4 (4.3%) |
Glioma | Â | 5 (3.2%) | 4 (4.3%) |
Melanoma | Â | 4 (2.6%) | 4 (4.3%) |
Mixed haematological cancers | Â | 8 (5.2%) | 0 (0%) |
CNS tumours | Â | 4 (2.6%) | 3 (3.2%) |
Head and neck cancer | Â | 4 (2.6%) | 3 (3.2%) |
Brain cancer | Â | 5 (3.2%) | 1 (1.1%) |
Lymphoma and advanced solid tumours | Â | 4 (2.6%) | 2 (2.2%) |
Sarcoma | Â | 3 (1.9%) | 3 (3.2%) |
CLL | Â | 3 (1.9%) | 2 (2.2%) |
Hepatocellular carcinoma | Â | 2 (1.3%) | 2 (2.2%) |
Renal cell carcinoma | Â | 2 (1.3%) | 2 (2.2%) |
Biliary tract cancer | Â | 3 (1.9%) | 0 (0%) |
Glioblastoma | Â | 2 (1.3%) | 1 (1.1%) |
NSCLC | Â | 2 (1.3%) | 1 (1.1%) |
SCLC | Â | 3 (1.9%) | 0 (0%) |
Cervical cancer | Â | 1 (0.6%) | 1 (1.1%) |